EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19

Ads

You May Also Like

Orphazyme reports encouraging arimoclomol clinical trial top-line data in Niemann-Pick disease Type C (NPC)

Orphazyme A/SCompany announcement                                                                                                                   No. 12/2018                                                                                                                                        Company Registration No. 32266355                                                                                                                                                                                              Arimoclomol was well-tolerated in patients ...